Show Hide image

Profits tumble for Novartis

First-quarter net profit falls by 18 per cent, partly due to suspension of production at a US manufa

The Swiss health-care company Novartis has reported a net income of $2.33bn for the first quarter of 2012 – an 18 per cent decline, compared to $2.82bn for the same period last year.

The results were affected by a strong US dollar and weaker sales of the blood-pressure drug Diovan, which faces patent expiry. New products have so far been unable to compensate entirely for the drop in Diovan sales. 

The company's net sales declined 2 per cent to $13.74bn (2011: $14.03bn), while operating income decreased 17 per cent to $2.82bn ($3.41bn).

However, net sales increased in the pharmaceuticals division by 2 per cent to $7.84bn (2011:7.7bn). Products launched since 2007 generated $2.6bn of net sales. These products – Lucentis, Tasigna, Afinitor and Gilenya – now represent 33 per cent of division sales, compared to 26 per cent in the same period last year. Afinitor, an oral inhibitor of the mTOR pathway used across multiple diseases, made a strong contribution in the first quarter, with sales of $143m. 

Alcon net sales increased 5 per cent to $2.54bn, led by strong growth in the surgical division (9 per cent). Ophthalmic pharmaceuticals sales grew 5 per cent, while vision care grew 1 per cent.

Sandoz net sales declined 10 per cent to $2.12bn, against a very strong first quarter last year ($2.37bn).

Vaccines and diagnostics net sales were down 19 per cent to $299m (2011: $371m) but the contrast was mainly due to an exceptionally strong first quarter in 2011, which benefited from the release of bulk pediatric shipments.

Net sales for consumer health – which comprises OTC and animal health – declined 20 per cent to $932m (2011: $1.17bn), impacted by the suspension of production at a factory in Lincoln, Nebraska. 

Joseph Jimenez, CEO of Novartis, said:

Novartis Pharmaceuticals and Alcon divisions delivered strong growth and operating leverage in the first quarter. Group net sales performance was impacted by Sandoz, which was up against a strong year-ago base with enoxaparin exclusivity, and by consumer health, which was impacted by the suspension of production at the Lincoln, Nebraska, manufacturing site.

We are making progress remediating the quality issues at the Lincoln site, as well as the three Sandoz production sites.
Show Hide image

We're hiring! Join the New Statesman as an editorial assistant

The NS is looking for a new recruit.

The New Statesman is hiring an editorial assistant, who will work across the website and magazine to help the office run smoothly. The ideal candidate will have excellent language skills, a passion for journalism, and the ability to work quickly and confidently under pressure.

The job is a broad one – you will need to understand the requirements of both halves of the magazine (politics and culture) as well as having an interest in the technical requirements of magazine and website production. Experience with podcasts and social media would be helpful.

The right person will have omnivorous reading habits and the ability to assimilate new topics at speed. You will be expected to help out with administration tasks around the office, so you must be willing to take direction and get involved with unglamorous tasks. There will be opportunities to write, but this will not form the main part of the job. (Our current editorial assistant is now moving on to a writing post.)

This is a full-time paid job, which would suit a recent graduate or someone who is looking for an entry into journalism. On the job training and help with career development will be offered.

Please apply with an email to Stephen Bush (Stephen. Bush @ with the subject line ‘Editorial Assistant application’.  

In your covering letter, please include a 300-word analysis of the strengths and weaknesses of the New Statesman. Please also include 500 words on what you consider to be the most interesting trend in British politics, and your CV as a Word document. 

The deadline for applications is noon on Monday 12th October.